<DOC>
	<DOCNO>NCT01627886</DOCNO>
	<brief_summary>This open label , randomise , balance , two-treatment , two-period , two-sequence , crossover , oral bioequivalence study .</brief_summary>
	<brief_title>Bioequivalence Study Ibandronate Sodium Tablets 150 mg Under Fasting Condition</brief_title>
	<detailed_description>Open-Label , Balanced , Randomized , Two-Treatment , Two-Sequence , Two-Period , Single-Dose , Crossover Oral Bioequivalence Study Of Ibandronate Sodium 150 mg Tablets Of Dr. Reddy 's Laboratories Limited , India And 'BONIVA® ' 150 mg ( Ibandronate Sodium ) Tablets Of Roche Laboratories Inc. , USA In Healthy , Adult , Human Subjects Under Fasting Conditions ( With As Many Postmenopausal Women As Possible ) .</detailed_description>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . The subject healthy human 18 year old . 2 . The subject screen within 21 day prior administration first dose study drug . 3 . The subject BMI 19 30 weight kg/ height2 meter . 4 . The subject able communicate effectively study personnel . 5 . The subject able give write informed consent participate study . If subject female volunteer 6 . Is child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence 7 . Is surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject ) 8 . Should postmenopausal healthy woman attain complete menopause menstruation least one year hormone replacement therapy . 9 . Should 17ßestradiol serum level ≤92 pmol/L , follicle stimulate hormone ( FSH ) ≥40 IU/L screening ( postmenopausal healthy woman ) 1 . The subject history allergic response Ibandronate relate drug . 2 . The subject significant disease clinically significant abnormal finding screen [ medical history , physical examination , laboratory evaluation , ECG , Xray vaginal ultrasonography recording ( female subject ) ] 3 . The subject disease condition might compromise haemopoietic , gastrointestinal , renal , hepatic , cardiovascular , respiratory , central nervous system , diabetes , psychosis body system . 4 . The subject history presence bronchial asthma . 5 . The subject use enzymemodifying drug within 30 day prior receive first dose study medication . 6 . The subject history drug dependence , recent history alcoholism moderate alcohol us . 7 . The subject smoker smoke equal 10 cigarette per day equal 20 biddy per day refrain smoke study period . 8 . The subject history difficulty donate blood difficulty accessibility vein . 9 . The subject donate 1 unit ( 350 ml / 450 ml ) blood within 90 day prior receive first dose study medication . 10 . The subject positive hepatitis screen ( include subtypes A , B , C &amp; E ) . 11 . The subject positive test result HIV antibody / syphilis ( RPR/VDRL ) . 12 . The subject receive investigational product , participated drug research study within period 90 day prior first dose study medication administration . 13 . Female volunteer demonstrate positive pregnancy screen . 14 . Female volunteer currently breastfeed . 15 . Female volunteer willing use contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Ibandronate Sodium</keyword>
	<keyword>crossover</keyword>
</DOC>